Literature DB >> 27035987

Output-driven feedback system control platform optimizes combinatorial therapy of tuberculosis using a macrophage cell culture model.

Aleidy Silva1, Bai-Yu Lee2, Daniel L Clemens2, Theodore Kee3, Xianting Ding4, Chih-Ming Ho5, Marcus A Horwitz6.   

Abstract

Tuberculosis (TB) remains a major global public health problem, and improved treatments are needed to shorten duration of therapy, decrease disease burden, improve compliance, and combat emergence of drug resistance. Ideally, the most effective regimen would be identified by a systematic and comprehensive combinatorial search of large numbers of TB drugs. However, optimization of regimens by standard methods is challenging, especially as the number of drugs increases, because of the extremely large number of drug-dose combinations requiring testing. Herein, we used an optimization platform, feedback system control (FSC) methodology, to identify improved drug-dose combinations for TB treatment using a fluorescence-based human macrophage cell culture model of TB, in which macrophages are infected with isopropyl β-D-1-thiogalactopyranoside (IPTG)-inducible green fluorescent protein (GFP)-expressing Mycobacterium tuberculosis (Mtb). On the basis of only a single screening test and three iterations, we identified highly efficacious three- and four-drug combinations. To verify the efficacy of these combinations, we further evaluated them using a methodologically independent assay for intramacrophage killing of Mtb; the optimized combinations showed greater efficacy than the current standard TB drug regimen. Surprisingly, all top three- and four-drug optimized regimens included the third-line drug clofazimine, and none included the first-line drugs isoniazid and rifampin, which had insignificant or antagonistic impacts on efficacy. Because top regimens also did not include a fluoroquinolone or aminoglycoside, they are potentially of use for treating many cases of multidrug- and extensively drug-resistant TB. Our study shows the power of an FSC platform to identify promising previously unidentified drug-dose combinations for treatment of TB.

Entities:  

Keywords:  Mycobacterium tuberculosis; drug combination optimization; feedback system control; tuberculosis

Mesh:

Substances:

Year:  2016        PMID: 27035987      PMCID: PMC4839402          DOI: 10.1073/pnas.1600812113

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  17 in total

Review 1.  Global tuberculosis drug development pipeline: the need and the reality.

Authors:  Zhenkun Ma; Christian Lienhardt; Helen McIlleron; Andrew J Nunn; Xiexiu Wang
Journal:  Lancet       Date:  2010-05-18       Impact factor: 79.321

2.  Closed-loop control of cellular functions using combinatory drugs guided by a stochastic search algorithm.

Authors:  Pak Kin Wong; Fuqu Yu; Arash Shahangian; Genhong Cheng; Ren Sun; Chih-Ming Ho
Journal:  Proc Natl Acad Sci U S A       Date:  2008-03-20       Impact factor: 11.205

3.  Clofazimine shortens the duration of the first-line treatment regimen for experimental chemotherapy of tuberculosis.

Authors:  Sandeep Tyagi; Nicole C Ammerman; Si-Yang Li; John Adamson; Paul J Converse; Rosemary V Swanson; Deepak V Almeida; Jacques H Grosset
Journal:  Proc Natl Acad Sci U S A       Date:  2015-01-05       Impact factor: 11.205

Review 4.  Current development and future prospects in chemotherapy of tuberculosis.

Authors:  Eric L Nuermberger; Melvin K Spigelman; Wing Wai Yew
Journal:  Respirology       Date:  2010-06-04       Impact factor: 6.424

Review 5.  Tuberculosis treatment and management--an update on treatment regimens, trials, new drugs, and adjunct therapies.

Authors:  Alimuddin Zumla; Jeremiah Chakaya; Rosella Centis; Lia D'Ambrosio; Peter Mwaba; Matthew Bates; Nathan Kapata; Thomas Nyirenda; Duncan Chanda; Sayoki Mfinanga; Michael Hoelscher; Markus Maeurer; Giovanni Battista Migliori
Journal:  Lancet Respir Med       Date:  2015-03-09       Impact factor: 30.700

6.  Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis.

Authors:  Deepak Almeida; Eric Nuermberger; Rokeya Tasneen; Ian Rosenthal; Sandeep Tyagi; Kathy Williams; Charles Peloquin; Jacques Grosset
Journal:  Antimicrob Agents Chemother       Date:  2009-07-20       Impact factor: 5.191

7.  Bactericidal activity of streptomycin, isoniazid, rifampin, ethambutol, and pyrazinamide alone and in combination against Mycobacterium Tuberculosis.

Authors:  J M Dickinson; V R Aber; D A Mitchison
Journal:  Am Rev Respir Dis       Date:  1977-10

8.  The metabolic activity of Mycobacterium tuberculosis, assessed by use of a novel inducible GFP expression system, correlates with its capacity to inhibit phagosomal maturation and acidification in human macrophages.

Authors:  Bai-Yu Lee; Daniel L Clemens; Marcus A Horwitz
Journal:  Mol Microbiol       Date:  2008-03-19       Impact factor: 3.501

9.  Cascade search for HSV-1 combinatorial drugs with high antiviral efficacy and low toxicity.

Authors:  Xianting Ding; David Jesse Sanchez; Arash Shahangian; Ibrahim Al-Shyoukh; Genhong Cheng; Chih-Ming Ho
Journal:  Int J Nanomedicine       Date:  2012-05-10

10.  A streamlined search technology for identification of synergistic drug combinations.

Authors:  Andrea Weiss; Robert H Berndsen; Xianting Ding; Chih-Ming Ho; Paul J Dyson; Hubert van den Bergh; Arjan W Griffioen; Patrycja Nowak-Sliwinska
Journal:  Sci Rep       Date:  2015-09-29       Impact factor: 4.379

View more
  18 in total

Review 1.  Enabling Technologies for Personalized and Precision Medicine.

Authors:  Dean Ho; Stephen R Quake; Edward R B McCabe; Wee Joo Chng; Edward K Chow; Xianting Ding; Bruce D Gelb; Geoffrey S Ginsburg; Jason Hassenstab; Chih-Ming Ho; William C Mobley; Garry P Nolan; Steven T Rosen; Patrick Tan; Yun Yen; Ali Zarrinpar
Journal:  Trends Biotechnol       Date:  2020-01-21       Impact factor: 19.536

2.  PLK1 and NOTCH Positively Correlate in Melanoma and Their Combined Inhibition Results in Synergistic Modulations of Key Melanoma Pathways.

Authors:  Shengqin Su; Gagan Chhabra; Mary A Ndiaye; Chandra K Singh; Ting Ye; Wei Huang; Colin N Dewey; Vijayasaradhi Setaluri; Nihal Ahmad
Journal:  Mol Cancer Ther       Date:  2020-11-11       Impact factor: 6.009

3.  A Bioengineered Three-Dimensional Cell Culture Platform Integrated with Microfluidics To Address Antimicrobial Resistance in Tuberculosis.

Authors:  Magdalena K Bielecka; Liku B Tezera; Robert Zmijan; Francis Drobniewski; Xunli Zhang; Suwan Jayasinghe; Paul Elkington
Journal:  mBio       Date:  2017-02-07       Impact factor: 7.867

4.  Drug regimens identified and optimized by output-driven platform markedly reduce tuberculosis treatment time.

Authors:  Bai-Yu Lee; Daniel L Clemens; Aleidy Silva; Barbara Jane Dillon; Saša Masleša-Galić; Susana Nava; Xianting Ding; Chih-Ming Ho; Marcus A Horwitz
Journal:  Nat Commun       Date:  2017-01-24       Impact factor: 14.919

Review 5.  Searching Synergistic Dose Combinations for Anticancer Drugs.

Authors:  Zuojing Yin; Zeliang Deng; Wenyan Zhao; Zhiwei Cao
Journal:  Front Pharmacol       Date:  2018-05-22       Impact factor: 5.810

6.  Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility.

Authors:  Bai-Yu Lee; Daniel L Clemens; Aleidy Silva; Barbara Jane Dillon; Saša Masleša-Galić; Susana Nava; Chih-Ming Ho; Marcus A Horwitz
Journal:  PLoS One       Date:  2018-11-14       Impact factor: 3.240

7.  Artificial intelligence enabled parabolic response surface platform identifies ultra-rapid near-universal TB drug treatment regimens comprising approved drugs.

Authors:  Daniel L Clemens; Bai-Yu Lee; Aleidy Silva; Barbara Jane Dillon; Saša Masleša-Galić; Susana Nava; Xianting Ding; Chih-Ming Ho; Marcus A Horwitz
Journal:  PLoS One       Date:  2019-05-10       Impact factor: 3.240

8.  On-demand serum-free media formulations for human hematopoietic cell expansion using a high dimensional search algorithm.

Authors:  Michelle M Kim; Julie Audet
Journal:  Commun Biol       Date:  2019-02-01

9.  Applying optimization algorithms to tuberculosis antibiotic treatment regimens.

Authors:  Joseph M Cicchese; Elsje Pienaar; Denise E Kirschner; Jennifer J Linderman
Journal:  Cell Mol Bioeng       Date:  2017-08-30       Impact factor: 2.321

10.  Prediction of drug cocktail effects when the number of measurements is limited.

Authors:  Anat Zimmer; Avichai Tendler; Itay Katzir; Avi Mayo; Uri Alon
Journal:  PLoS Biol       Date:  2017-10-26       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.